Cited by 234Immune Cell Function and InteractionImmunotherapy and Immune ResponsesReproductive System and Pregnancy

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells

Open access

Carlsten, Mattias, Björkström, Niklas K., Norell, Håkan, Bryceson, Yenan, van Hall, Thorbald, Baumann, Bettina C., Hanson, Mikael, Schedvins, Kjell, Kiessling, Rolf, Ljunggren, Hans-Gustaf, Malmberg, Karl-Johan·2007·Cancer Research

DOI 10.1158/0008-5472.can-06-2264

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Although natural killer (NK) cells are well known for their ability to kill tumors, few studies have addressed the interactions between resting (nonactivated) NK cells and freshly isolated human tumors. Here, we show that human leukocyte antigen class Ilow tumor cells isolated directly from patients with advanced ovarian carcinoma trigger degranulation by resting allogeneic NK cells. This was paralleled by induction of granzyme B and caspase-6 activities in the tumor cells and significant tumor cell lysis. Ovarian carcinoma cells displayed ubiquitous expression of the DNAX accessory molecule-1 (DNAM-1) ligand PVR and sparse/heterogeneous expression of the NKG2D ligands MICA/MICB and ULBP1, ULBP2, and ULBP3. In line with the NK receptor ligand expression profiles, antibody-mediated blockade of activating receptor pathways revealed a dominant role for DNAM-1 and a complementary contribution of NKG2D signaling in tumor cell recognition. These results show that resting NK cells are capable of directly recognizing freshly isolated human tumor cells and identify ovarian carcinoma as a potential target for adoptive NK cell–based immunotherapy. [Cancer Res 2007;67(3):1317–25]

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-2264

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272
NK CELL RECOGNITION
Lanier, L. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,765
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Self-citation
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894
„Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype
Kiessling, R. W., Klein, E., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050208 · Cited by 1,827
Self-citation
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation
Betts, M. R., Brenchley, J. M., Price, D. A., Rosa, S. C. D., Douek, D. C., Roederer, M., & Koup, R. A. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00265-5 · Cited by 1,596
CD107a as a functional marker for the identification of natural killer cell activity
Alter, G., Malenfant, J., & Altfeld, M. A. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.08.008 · Cited by 1,416
ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W. A., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,394
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J. M., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,181

Show all 40 references

Sorted by citations

Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Long, E. O., Kim, H. S., Liu, D., Peterson, M., & Rajagopalan, S. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075005 · Cited by 1,258
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H., & Bryceson, Y. T. (2009) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 894
Self-citation
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans
Solana, R., Tarazona, R., Gayoso, I., Lesur, O., Dupuis, G., & Fulop, T. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.04.008 · Cited by 567
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H., & Malmberg, K. (2007) · Nature reviews. Immunology · doi:10.1038/nri2073 · Cited by 538
Self-citation
Immunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510
ATM-ATR–dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R. G., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis‐Mortari, A., Curtsinger, J., McKenna, D. H., et al. (2010) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 451
TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy
Dougall, W. C., Kurtuluş, S., Smyth, M. J., & Anderson, A. C. (2017) · Immunological Reviews · doi:10.1111/imr.12518 · Cited by 432
NKG2D ligands in tumor immunity
Nausch, N., & Cerwenka, A. (2008) · Oncogene · doi:10.1038/onc.2008.272 · Cited by 422
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature reviews. Immunology · doi:10.1038/nri2604 · Cited by 405
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C. M., Howard, E. D., Chadwick, E. M., Johnston, J. V., Hammond, A. J., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 361
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36022 · Cited by 347
The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells
El-Sherbiny, Y. M., Meade, J. L., Holmes, T. D., McGonagle, D. G., Mackie, S. L., Morgan, A. W., Cook, G., Feyler, S., Richards, S. J., Davies, F. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4230 · Cited by 320
Natural killer cell-mediated immunosurveillance of human cancer
Malmberg, K., Carlsten, M., Björklund, A. T., Sohlberg, E., Bryceson, Y. T., & Ljunggren, H. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.002 · Cited by 301
Self-citation
Accelerated tumor growth in mice deficient in DNAM-1 receptor
Iguchi‐Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara‐Hanaoka, S., Honda, S.-I., Yasui, T., Kikutani, H., Shibuya, K., & Shibuya, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081611 · Cited by 289
Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
Carlsten, M., Norell, H., Bryceson, Y. T., Poschke, I. C., Schedvins, K., Ljunggren, H., Kiessling, R. W., & Malmberg, K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901226 · Cited by 283
Self-citation
Natural killer cells
Mandal, A., & Viswanathan, C. (2014) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2014.11.006 · Cited by 289
Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules
Tallerico, R., Todaro, M., Franco, S. D., Maccalli, C., Garofalo, C., Sottile, R., Palmieri, C., Tirinato, L., Pangigadde, P., Rocca, R. L., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201542 · Cited by 251
Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells
Correia, D. V., Fogli, M., Hudspeth, K. L., da Silva, M. G., Mavilio, D., & Silva‐Santos, B. (2011) · Blood · doi:10.1182/blood-2011-02-339135 · Cited by 236
Decreased expression of DNAM‐1 on NK cells from acute myeloid leukemia patients
Sanchez‐Correa, B., Gayoso, I., Bergua, J. M., Casado, J. G., Morgado, S., Solana, R., & Tarazona, R. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.15 · Cited by 228
NKG2D ligands as therapeutic targets.
(2013) · Europe PMC (PubMed Central) · Cited by 218
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
Sánchez-Correa, B., Valhondo, I., Hassouneh, F., López-Sejas, N., Pera, A., Bergua, J., Arcos, M. J., Bañas, H., Casas-Avilés, I., Durán, E., et al. (2019) · Cancers · doi:10.3390/cancers11060877 · Cited by 217
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Gubbels, J. A. A., Felder, M. A. R., Horibata, S., Belisle, J. A., Kapur, A., Holden, H., Petrie, S. E., Migneault, M., Rancourt, C., Connor, J. P., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-11 · Cited by 219
Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity
Samanta, D., & Almo, S. C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1763-4 · Cited by 209
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 207
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Alici, E., Sütlü, T., Björkstrand, B., Gilljam, M., Stellan, B., Nahi, H., Quezada, H. C., Gahrton, G., Ljunggren, H., & Dilber, M. S. (2008) · Blood · doi:10.1182/blood-2007-09-110312 · Cited by 197
Self-citation
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
Mercier, I. L., Lines, J. L., & Noelle, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00418 · Cited by 202
DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases
Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita∥, H., Gilfillan, S., Colonna, M., & Smyth, M. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0903225 · Cited by 191
B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
Pesce, S., Tabellini, G., Cantoni, C., Patrizi, O., Coltrini, D., Rampinelli, F., Matta, J., Vivier, É., Moretta, A., Parolini, S., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1001224 · Cited by 178
Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity
Wilson, E., El‐Jawhari, J. J., Neilson, A. L., Hall, G. D., Melcher, A. A., Meade, J. L., & Cook, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022842 · Cited by 187
Targeting PVR (CD155) and its receptors in anti-tumor therapy
Brlić, P. K., Roviš, T. L., Cinamon, G., Tsukerman, P., Mandelboim, O., & Jonjić, S. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0168-y · Cited by 172
Use of Allogeneic NK Cells for Cancer Immunotherapy
Geller, M. A., & Miller, J. S. (2011) · Immunotherapy · doi:10.2217/imt.11.131 · Cited by 163
Neuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells
Castriconi, R., Dondero, A., Bellora, F., Moretta, L., Castellano, A., Locatelli, F., Corrias, M. V., Moretta, A., & Bottino, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202693 · Cited by 159
Cancer exosomes and NKG2D receptor–ligand interactions: Impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance
Mincheva‐Nilsson, L., & Baranov, V. I. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.02.010 · Cited by 143
Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines
Casado, J. G., Pawelec, G., Morgado, S., Sánchez-Correa, B., Delgado, E., Gayoso, I., Durán, E., Solana, R., & Tarazona, R. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0682-y · Cited by 140
Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients
Rocca, Y., Roberti, M. P., Arriaga, J. M., Amat, M., Bruno, L. I., Pampena, M. B., Huertas, E., Loria, F. S., Pairola, A., Bianchini, M., et al. (2012) · Innate Immunity · doi:10.1177/1753425912453187 · Cited by 144
IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
Felices, M., Chu, S., Kodal, B., Bendzick, L. E., Ryan, C. J., Lenvik, A. J., Boylan, K. L. M., Wong, H. C., Skubitz, A. P. N., Miller, J. S., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.02.028 · Cited by 138
DNAX accessory molecule‐1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells
Toutirais, O., Cabillic, F., Friec, G. L., Salot, S., Loyer, P., Gallo, M. L., Desille, M., Pintière, C. T. D. L., Daniel, P., Bouet, F., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200838409 · Cited by 132
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
Baci, D., Bosi, A., Gallazzi, M., Rizzi, M., Noonan, D. M., Poggi, A. D., Bruno, A., & Mortara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093125 · Cited by 133
The Human Immunodeficiency Virus Type 1 Nef and Vpu Proteins Downregulate the Natural Killer Cell-Activating Ligand PVR
Matusali, G., Potestà, M., Santoni, A., Cerboni, C., & Doria, M. (2012) · Journal of Virology · doi:10.1128/jvi.05788-11 · Cited by 132
Human Vγ9Vδ2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts
Gertner-Dardenne, J., Castellano, R., Mamessier, É., Garbit, S., Kochbati, E., Etienne, A., Charbonnier, A., Collette, Y., Vey, N., & Olive, D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103710 · Cited by 128
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways
Verhoeven, D. H. J., de Hooge, A. S. K., Mooiman, E., Santos, S. J., ten Dam, M. M., Gelderblom, H. A. J., Melief, C. J. M., Hogendoorn, P. C. W., Egeler, R. M., van Tol, M. J. D., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.016 · Cited by 125
Synergistic Signals for Natural Cytotoxicity Are Required to Overcome Inhibition by c-Cbl Ubiquitin Ligase
Kim, H. S., Das, A., Groß, C. C., Bryceson, Y. T., & Long, E. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.02.004 · Cited by 128
Self-citation
Coming of Age: CD96 Emerges as Modulator of Immune Responses
Georgiev, H., Ravens, I., Papadogianni, G., & Bernhardt, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01072 · Cited by 115
CD155: A Multi-Functional Molecule in Tumor Progression
Molfetta, R., Zitti, B., Lecce, M., Milito, N. D., Stabile, H., Fionda, C., Cippitelli, M., Gismondi, A., Santoni, A., & Paolini, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030922 · Cited by 113
Increased Soluble CD155 in the Serum of Cancer Patients
Iguchi‐Manaka, A., Okumura, G., Kojima, H., Cho, Y., Hirochika, R., Bando, H., Sato, T., Yoshikawa, H., Hara, H., Shibuya, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152982 · Cited by 113
New views on natural killer cell-based immunotherapy for melanoma treatment
Burke, S., Lakshmikanth, T., Colucci, F., & Carbone, E. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.003 · Cited by 107
Natural Killer Cells and Neuroblastoma: Tumor Recognition, Escape Mechanisms, and Possible Novel Immunotherapeutic Approaches
Bottino, C., Dondero, A., Bellora, F., Moretta, L., Locatelli, F., Pistoia, V., Moretta, A., & Castriconi, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00056 · Cited by 106
CD96 functions as a co‐stimulatory receptor to enhance CD8 + T cell activation and effector responses
Chiang, E. Y., de Almeida, P. E., Nagata, D. D. A., Bowles, K. H., Du, X., Chitre, A. S., Banta, K. L., Kwon, Y. C., McKenzie, B. S., Mittman, S., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.201948405 · Cited by 107
CD226: An Emerging Role in Immunologic Diseases
Huang, Z., Qi, G., Miller, J. S., & Zheng, S. G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00564 · Cited by 101
NK cells to cure cancer
Vito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 104
Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells
Enqvist, M., Ask, E. H., Forslund, E., Carlsten, M., Abrahamsen, G., Béziat, V., Andersson, S., Schaffer, M., Spurkland, A., Bryceson, Y. T., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401972 · Cited by 100
Self-citation
The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1
Seth, S., Maier, M. K., Qiu, Q., Ravens, I., Kremmer, E., Förster, R., & Bernhardt, G. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.102 · Cited by 99
Expression of Chimeric Receptor CD4 ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo
Ni, Z., Knorr, D. A., Bendzick, L. E., Allred, J. R., & Kaufman, D. S. (2013) · Stem Cells · doi:10.1002/stem.1611 · Cited by 99
Human Pluripotent Stem Cells Produce Natural Killer Cells That Mediate Anti-HIV-1 Activity by Utilizing Diverse Cellular Mechanisms
Ni, Z., Knorr, D. A., Clouser, C. L., Hexum, M. K., Southern, P. J., Mansky, L. M., Park, I., & Kaufman, D. S. (2010) · Journal of Virology · doi:10.1128/jvi.01774-10 · Cited by 97
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 95
Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity
Labani‐Motlagh, A., Israelsson, P., Ottander, U., Lundin, E., Nagaev, I., Nagaeva, O., Dehlin, E., Baranov, V. I., & Mincheva‐Nilsson, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-4313-2 · Cited by 93
A robust platform for expansion and genome editing of primary human natural killer cells
Huang, R., Lai, M., Shih, H.-A., & Lin, S. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201529 · Cited by 86
Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade
Cluxton, C. D., Spillane, C. D., O’Toole, S. A., Sheils, O. M., Gardiner, C. M., & O’Leary, J. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211538 · Cited by 90
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg, K., Bryceson, Y. T., Carlsten, M., Andersson, S., Björklund, A. T., Björkström, N. K., Baumann, B. C., Fauriat, C., Alici, E., Dilber, M. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0492-7 · Cited by 89
Self-citation
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
Li, H., Song, W., Li, Z., & Zhang, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992232 · Cited by 95
Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer
Barber, A. E., Zhang, T., & Sentman, C. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.72 · Cited by 83
NK Cell Therapy: A Rising Star in Cancer Treatment
Du, N., Guo, F.-F., Wang, Y.-F., & Cui, J. (2021) · Cancers · doi:10.3390/cancers13164129 · Cited by 72
Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
Matuszewska, K., Santry, L. A., van Vloten, J. P., AuYeung, A. W. K., Major, P. P., Lawler, J., Wootton, S. K., Bridle, B. W., & Petrik, J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0220 · Cited by 81
Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials
Suen, C.-W. W., Lee, W., Leung, K. T., Pan, X., & Li, G. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1515315 · Cited by 80
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
Palaia, I., Tomao, F., Sassu, C. M., Musacchio, L., & Panici, P. B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s205950 · Cited by 84
Newtonian cell interactions shape natural killer cell education
Goodridge, J. P., Önfelt, B., & Malmberg, K. (2015) · Immunological Reviews · doi:10.1111/imr.12325 · Cited by 74
Self-citation
Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model
Geller, M. A., Knorr, D. A., Hermanson, D., Pribyl, L. J., Bendzick, L. E., McCullar, V., Miller, J. S., & Kaufman, D. S. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.05.022 · Cited by 73
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
Maas, R. J. A., Evert, J. S. H., der Meer, J. M. R. V., Mekers, V. E., Rezaeifard, S., Korman, A. J., de Jonge, P. K. J. D., Cany, J., Woestenenk, R., Schaap, N. P., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1843247 · Cited by 73
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
Buckle, I., & Guillerey, C. (2021) · Cancers · doi:10.3390/cancers13174263 · Cited by 74
The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia
Giamougiannis, P., Martin‐Hirsch, P. L., & Martin, F. L. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab010 · Cited by 75
Immune Response in Ovarian Cancer: How Is the Immune SystemInvolved in Prognosis and Therapy: Potential for Treatment Utilization
Gavalas, N. G., Karadimou, A., Dimopoulos, M. A., & Bamias, A. (2010) · Journal of Immunology Research · doi:10.1155/2010/791603 · Cited by 73
Human Herpesvirus 8 (HHV8) Sequentially Shapes the NK Cell Repertoire during the Course of Asymptomatic Infection and Kaposi Sarcoma
Dupuy, S., Lambert, M., Zucman, D., Choukem, S. P., Tognarelli, S., Pagès, C., Lebbé, C., & Caillat‐Zucman, S. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002486 · Cited by 67
Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing
Kearney, C. J., Ramsbottom, K. M., Voskoboinik, I., Darcy, P. K., & Oliaro, J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196308 · Cited by 68
Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
Gorvel, L., & Olive, D. (2020) · F1000Research · doi:10.12688/f1000research.22877.1 · Cited by 65
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy
Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Zhao, X., Yu, Y., Zhang, H., Xu, F., & Tian, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02068-5 · Cited by 64
Multi-omics characterization of silent and productive HPV integration in cervical cancer
Fan, J., Fu, Y., Peng, W., Li, X., Shen, Y., Guo, E., Lu, F., Zhou, S., Liu, S., Yang, B., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2022.100211 · Cited by 61
Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell–Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
Wennerberg, E., Pfefferle, A., Ekblad, L., Yoshimoto, Y., Kremer, V., Kaminskyy, V. O., Juhlin, C. C., Höög, A., Bodin, I., Svjatoha, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0291 · Cited by 61
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 61
DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses
Shibuya, A., & Shibuya, K. (2021) · International Immunology · doi:10.1093/intimm/dxab085 · Cited by 60
Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
Ren, X., Peng, M., Peng, X., Yao, W., Galbo, P. M., Corrigan, D. T., Wang, H., Su, Y., Dong, X., Sun, Q., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163620 · Cited by 59
UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell‐mediated cytotoxicity in hepatoma cells
Gong, J.-Y., Fang, L., Liu, R., Wang, Y., Xing, J., Chen, Y.-B., Zhuang, R., Zhang, Y., Zhang, C.-M., Yang, A., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201444574 · Cited by 50
Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line
Bae, D. S., & Lee, J. K. (2014) · Blood Research · doi:10.5045/br.2014.49.3.154 · Cited by 55
NK cell-based cancer immunotherapy: from basic biology to clinical application
Li, Y., Yin, J., Li, T., Huang, S., Yan, H., Leavenworth, J. W., & Wang, X. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4970-9 · Cited by 55
Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model
Poznanski, S. M., Nham, T., Chew, M. V., Lee, A. J., Hammill, J. A., Fan, I. Y., Butcher, M. K., Bramson, J. L., Lee, D. A., Hirte, H. W., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0144 · Cited by 54
The Notch Ligands Jagged2, Delta1, and Delta4 Induce Differentiation and Expansion of Functional Human NK Cells from CD34+ Cord Blood Hematopoietic Progenitor Cells
Beck, R. C., Padival, M., Yeh, D., Ralston, J., Cooke, K. R., & Lowe, J. B. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.06.002 · Cited by 52
Immunosenescence: limitations of natural killer cell-based cancer immunotherapy
Tarazona, R., Sánchez-Correa, B., Casas-Avilés, I., Campos, C., Pera, A., Morgado, S., López-Sejas, N., Hassouneh, F., Bergua, J., Arcos, M. J., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1882-x · Cited by 53
Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells
Enqvist, M., Nilsonne, G., Hammarfjord, O., Wallin, R. P. A., Björkström, N. K., Björnstedt, M., Hjerpe, A., Ljunggren, H., Dobra, K., Malmberg, K., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100610 · Cited by 54
Self-citation
Tissue‐specific effector functions of innate lymphoid cells
Björkström, N. K., Kekäläinen, E., & Mjösberg, J. (2013) · Immunology · doi:10.1111/imm.12098 · Cited by 53
Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies
Marrella, A., Dondero, A., Aiello, M., Casu, B., Olive, D., Regis, S., Bottino, C., Pende, D., Meazza, R., Caluori, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01876 · Cited by 50
Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis
Alteber, Z., Kotturi, M. F., Whelan, S., Ganguly, S., Weyl, E., Pardoll, D. M., Hunter, J., & Ophir, E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1248 · Cited by 48
TGF-beta: a master switch in tumor immunity
Gigante, M., Gesualdo, L., & Ranieri, E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802430378 · Cited by 45
NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer
Leung, E. Y. L., Ennis, D. P., Kennedy, P. R., Hansell, C. A. H., Dowson, S., Farquharson, M., Spiliopoulou, P., Nautiyal, J., McNamara, S., Carlin, L. M., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.02.001 · Cited by 46
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
Zitti, B., Molfetta, R., Fionda, C., Quatrini, L., Stabile, H., Lecce, M., de Turris, V., Ricciardi, M. R., Petrucci, M. T., Cippitelli, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10403-0 · Cited by 44
CD226 Protein Is Involved in Immune Synapse Formation and Triggers Natural Killer (NK) Cell Activation via Its First Extracellular Domain
Hou, S., Ge, K., Zheng, X., Wei, H., Sun, R., & Tian, Z. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498253 · Cited by 43
Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki, T., Onishi, H., & Katano, M. (2012) · PubMed · Cited by 43
Interferon α–Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1
Stegmann, K. A., Björkström, N. K., Ciesek, S., Lunemann, S., Jaroszewicz, J., Wiegand, J., Malinski, P., Dustin, L. B., Rice, C. M., Manns, M. P., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis210 · Cited by 42
Self-citation
Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
Stamm, H., Wellbrock, J., & Fiedler, W. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9770-7 · Cited by 41
The Ubiquitin‐proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing
Molfetta, R., Milito, N. D., Zitti, B., Lecce, M., Fionda, C., Cippitelli, M., Santoni, A., & Paolini, R. (2018) · European Journal of Immunology · doi:10.1002/eji.201847848 · Cited by 39

Authors: Carlsten, M., Björkström, N. K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B. C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.-G., & Malmberg, K.-J.
Affiliations: Karolinska University Hospital (SE)
1Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge;
2Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Department of Oncology and Pathology, Karolinska Institutet;
Karolinska Institutet (SE)
ORCID: Carlsten, Mattias
Bryceson, Yenan
Kiessling, Rolf
Ljunggren, Hans-Gustaf
Malmberg, Karl-Johan
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2007-02-01
Volume: 67
Issue: 3
Pages: 1317-1325
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-06-2264
OpenAlex: W2104794630
Cited by: 234
References: 40
Citations by year: 2026: 3 · 2025: 3 · 2024: 8 · 2023: 10 · 2022: 7 · 2021: 14 · 2020: 18 · 2019: 11 · 2018: 16 · 2017: 14 · 2016: 11 · 2015: 14 · 2014: 14 · 2013: 14 · 2012: 14
FWCI: 5.33
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: Novartis Foundation
Stiftelsen för Strategisk Forskning
Cancerfonden
Svenska Sällskapet för Medicinsk Forskning
Karolinska Institutet
Vetenskapsrådet
National Institutes of Health
National Cancer Institute (R01CA102280, CA 102280)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
Keywords: DNAM-1, PVR, NKG2D, ovarian carcinoma, NK cell degranulation, granzyme B, caspase-6, ULBP, tumor cell lysis, NK cell therapy, cancer cell detection
MeSH terms: T Lineage-Specific Activation Antigen 1, Antigens, Differentiation, T-Lymphocyte, Female, Humans, Killer Cells, Natural, Ligands, Ovarian Neoplasms, Receptors, Immunologic, Cell Degranulation, K562 Cells, Granzymes, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks